Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 681 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
16 Results
Screening In Anticipation of Future Research
- Hepatitis
- HIV/AIDS
- Immune System
- Infectious Disease
- Gender:All Genders
- Age:2 years - 17 years
The Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis
- Children's Health
- Liver
- Gender:All Genders
- Age:12 years - 30 years
A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders
- Leukemia & Hematologic Cancers
- Pediatric Cancers
- Gender:All Genders
- Age:21 years and younger
Effects of Hepatic Ultrasound on Metabolic Homeostasis
- Liver
- Obesity & Weight Management
- Gender:All Genders
- Age:18 years - 60 years
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Colorectal Cancer
Testing Atezolizumab with Selinexor in People ≥ 12 Years Old with Alveolar Soft Part Sarcoma, The AXIOM Trial
- Sarcoma Cancers
A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants With Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
- Skin Cancers & Melanoma
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
- Gynecological Cancers
Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy
- Lung Cancer
A Phase II Trial to Improve Safety of Capivasertib for HR+/HER2- Metastatic Breast Cancer
- Breast Cancer
1-10 of 16 Results